Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy.

Kacherovsky N, Cardle II, Cheng EL, Yu JL, Baldwin ML, Salipante SJ, Jensen MC, Pun SH.

Nat Biomed Eng. 2019 Jun 17. doi: 10.1038/s41551-019-0411-6. [Epub ahead of print]

PMID:
31209354
2.

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.

Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, Gamble DN, Rawlings-Rhea SD, Khalatbari HK, Ishak GE, Duncan VE, Hevner RF, Jensen MC, Park JR, Gardner RA.

Ann Neurol. 2019 Jul;86(1):42-54. doi: 10.1002/ana.25502. Epub 2019 May 27.

PMID:
31074527
3.

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies.

Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, Cardle II, Johnson A, Gustafson J, Parker N, Vetzel M, Xu LC, Wang EZ, Jensen MC, Klein PJ, Low PS, Leamon CP.

Front Oncol. 2019 Mar 19;9:151. doi: 10.3389/fonc.2019.00151. eCollection 2019.

4.

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA, Jensen MC.

J Clin Invest. 2019 Mar 12;130. pii: 125423. doi: 10.1172/JCI125423.

5.

Cell-Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen-Presenting Cells for T Cell Activation.

Olden BR, Perez CR, Wilson AL, Cardle II, Lin YS, Kaehr B, Gustafson JA, Jensen MC, Pun SH.

Adv Healthc Mater. 2019 Jan;8(2):e1801188. doi: 10.1002/adhm.201801188. Epub 2018 Dec 13.

PMID:
30549244
6.

Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.

Künkele A, Brown C, Beebe A, Mgebroff S, Johnson AJ, Taraseviciute A, Rolczynski LS, Chang CA, Finney OC, Park JR, Jensen MC.

Biol Blood Marrow Transplant. 2019 Feb;25(2):223-232. doi: 10.1016/j.bbmt.2018.10.004. Epub 2018 Oct 10.

PMID:
30315942
7.

The effect of glenohumeral plane of elevation on supraspinatus subacromial proximity.

Lawrence RL, Sessions WC, Jensen MC, Staker JL, Eid A, Breighner R, Helwig NE, Braman JP, Ludewig PM.

J Biomech. 2018 Oct 5;79:147-154. doi: 10.1016/j.jbiomech.2018.08.005. Epub 2018 Aug 13.

PMID:
30172354
8.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

9.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

10.

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.

Lee SY, Olsen P, Lee DH, Kenoyer AL, Budde LE, O'Steen S, Green DJ, Heimfeld S, Jensen MC, Riddell SR, Press OW, Till BG.

J Immunother. 2018 Jan;41(1):19-31. doi: 10.1097/CJI.0000000000000199.

11.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC.

Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.

12.

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.

Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaag2196. doi: 10.1126/scitranslmed.aag2196.

13.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B.

N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.

14.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH.

J Clin Invest. 2016 Nov 1;126(11):4262-4272. doi: 10.1172/JCI84813. Epub 2016 Oct 17.

15.

Crack Cocaine Use in Adolescents: Clinical Characteristics and Predictors of Early Initiation.

Pianca TG, Rohde LA, Rosa RL, Begnis AP, Ferronatto PB, Jensen MC, Pechansky F, Ceresér KM, Fairchild VP, Szobot CM.

J Clin Psychiatry. 2016 Oct;77(10):e1205-e1210. doi: 10.4088/JCP.15m09894.

PMID:
27574840
16.

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ.

Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.

17.

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility.

Künkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, Chang CA, Rolczynski LS, Brown C, Mgebroff S, Berger M, Park JR, Jensen MC.

Clin Cancer Res. 2017 Jan 15;23(2):466-477. doi: 10.1158/1078-0432.CCR-16-0354. Epub 2016 Jul 7.

18.

ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY.

Cancer Immunol Res. 2016 Jul;4(7):639-41. doi: 10.1158/2326-6066.CIR-16-0108. No abstract available.

19.

High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.

Gwiazda KS, Grier AE, Sahni J, Burleigh SM, Martin U, Yang JG, Popp NA, Krutein MC, Khan IF, Jacoby K, Jensen MC, Rawlings DJ, Scharenberg AM.

Mol Ther. 2016 Sep 29;24(9):1570-80. doi: 10.1038/mt.2016.105. Epub 2016 May 16.

20.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG.

Cancer Immunol Res. 2016 Jun;4(6):509-19. doi: 10.1158/2326-6066.CIR-15-0276. Epub 2016 Apr 21.

21.

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ.

Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.

22.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

23.

pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences.

Grier AE, Burleigh S, Sahni J, Clough CA, Cardot V, Choe DC, Krutein MC, Rawlings DJ, Jensen MC, Scharenberg AM, Jacoby K.

Mol Ther Nucleic Acids. 2016 Apr 19;5:e306. doi: 10.1038/mtna.2016.21.

24.

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY.

Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8.

25.

Comparison of naïve and central memory derived CD8+ effector cell engraftment fitness and function following adoptive transfer.

Wang X, Wong CW, Urak R, Taus E, Aguilar B, Chang WC, Mardiros A, Budde LE, Brown CE, Berger C, Forman SJ, Jensen MC.

Oncoimmunology. 2015 Aug 20;5(1):e1072671. eCollection 2016.

26.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

27.

L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.

Hong H, Brown CE, Ostberg JR, Priceman SJ, Chang WC, Weng L, Lin P, Wakabayashi MT, Jensen MC, Forman SJ.

PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.

28.

IMMUNOLOGY. Synthetic immunobiology boosts the IQ of T cells.

Jensen MC.

Science. 2015 Oct 30;350(6260):514-5. doi: 10.1126/science.aad5289. No abstract available.

PMID:
26516270
29.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR.

Mol Ther. 2016 Mar;24(3):570-81. doi: 10.1038/mt.2015.197. Epub 2015 Oct 27.

30.

Efficient Identification of Murine M2 Macrophage Peptide Targeting Ligands by Phage Display and Next-Generation Sequencing.

Liu GW, Livesay BR, Kacherovsky NA, Cieslewicz M, Lutz E, Waalkes A, Jensen MC, Salipante SJ, Pun SH.

Bioconjug Chem. 2015 Aug 19;26(8):1811-7. doi: 10.1021/acs.bioconjchem.5b00344. Epub 2015 Jul 28.

31.

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC.

Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9.

32.

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.

Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, Thomas SH, Brown CE, La Rosa C, Diamond DJ, Jensen MC, Nakamura R, Zaia JA, Forman SJ.

Clin Cancer Res. 2015 Jul 1;21(13):2993-3002. doi: 10.1158/1078-0432.CCR-14-2920. Epub 2015 Apr 2.

33.

Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection.

Kacherovsky N, Liu GW, Jensen MC, Pun SH.

Biotechnol Bioeng. 2015 Jul;112(7):1429-36. doi: 10.1002/bit.25538. Epub 2015 Mar 23.

PMID:
25808830
34.

A functionalized, injectable hydrogel for localized drug delivery with tunable thermosensitivity: synthesis and characterization of physical and toxicological properties.

Elias PZ, Liu GW, Wei H, Jensen MC, Horner PJ, Pun SH.

J Control Release. 2015 Jun 28;208:76-84. doi: 10.1016/j.jconrel.2015.03.003. Epub 2015 Mar 4.

PMID:
25747144
35.

Designing chimeric antigen receptors to effectively and safely target tumors.

Jensen MC, Riddell SR.

Curr Opin Immunol. 2015 Apr;33:9-15. doi: 10.1016/j.coi.2015.01.002. Epub 2015 Jan 23. Review.

36.

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC.

Cancer Immunol Res. 2015 Apr;3(4):368-79. doi: 10.1158/2326-6066.CIR-14-0200. Epub 2015 Jan 9.

37.

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11.

38.

Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy.

Tsao CT, Kievit FM, Ravanpay A, Erickson AE, Jensen MC, Ellenbogen RG, Zhang M.

Biomacromolecules. 2014 Jul 14;15(7):2656-62. doi: 10.1021/bm500502n. Epub 2014 Jun 25.

39.

Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.

Mahadev V, Starr R, Wright SL, Martinez C, Jensen MC, Barish ME, Forman SJ, Brown CE.

PLoS One. 2014 May 2;9(5):e95123. doi: 10.1371/journal.pone.0095123. eCollection 2014.

40.

CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster child.

Gardner RA, Jensen MC.

Cancer J. 2014 Mar-Apr;20(2):107-11. doi: 10.1097/PPO.0000000000000030. Review.

PMID:
24667954
41.

Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.

Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

J Immunother. 2014 Feb-Mar;37(2):93-104. doi: 10.1097/CJI.0000000000000018.

PMID:
24509172
42.

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.

Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW.

PLoS One. 2013 Dec 17;8(12):e82742. doi: 10.1371/journal.pone.0082742. eCollection 2013.

43.

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Jensen MC, Riddell SR.

Immunol Rev. 2014 Jan;257(1):127-44. doi: 10.1111/imr.12139. Review. Erratum in: Immunol Rev. 2014 Mar;258(1):259.

44.

The dynamics of carbon dioxide equilibration after alterations in the respiratory rate.

Buehler S, Jensen MC, Lozano-Zahonero S, Gottlieb D, Eckle D, Szczyrba M, Schumann S, Moeller K, Guttmann J.

Physiol Meas. 2013 Sep;34(9):1151-61.

PMID:
24137705
45.

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.

Blood. 2013 Oct 31;122(18):3138-48. doi: 10.1182/blood-2012-12-474056. Epub 2013 Sep 12.

46.

Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.

Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

PLoS One. 2013 Jun 6;8(6):e65519. doi: 10.1371/journal.pone.0065519. Print 2013.

47.

Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.

Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC.

Mol Immunol. 2013 Nov;56(1-2):1-11. doi: 10.1016/j.molimm.2013.03.021. Epub 2013 Apr 27.

PMID:
23628622
48.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.

Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.

49.

Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

Gene Ther. 2013 Aug;20(8):853-60. doi: 10.1038/gt.2012.97. Epub 2013 Jan 10.

50.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

Supplemental Content

Loading ...
Support Center